Articles |
From the Faculty of Medicine, University of Oslo (H.E.R.); Research Forum, Ullevaal University Hospital (T.L.); the Department of Surgery, Ullevaal University Hospital (H.D.); Nycomed Bioreg AS (M.H., K.S.S.); the Clinical Chemistry Department, Ullevaal University Hospital (P.K., A.-B.W.); and the Department of Biology, Division of General Physiology, University of Oslo (K.S.S.), Oslo, Norway.
Correspondence to Dr Helge Einar Roald, University of Oslo, c/o Nycomed Bioreg AS, Gaustadalléen 21, 0371 Oslo, Norway.
| Abstract |
|---|
|
|
|---|
Key Words: cigarette smoking intermittent claudication peripheral arterial disease arterial blood flow thrombus formation
| Introduction |
|---|
|
|
|---|
Platelet reactivity is most often characterized through the response of platelets to an external agonist. To study platelet reactivity in flowing nonanticoagulated blood from these individuals, we used a parallel-plate perfusion device.6 7 Thrombogenesis was elicited by immobilized type III collagen fibrils, and platelet-collagen adherence and platelet thrombus formation on the collagen surface were quantified. This model was previously validated by correlation with simultaneously induced experimental in vivo coronary thrombosis in dogs.8 Other results obtained with this model correlate well with clinical findings in humans, eg, in patients with factor VIII deficiency and various subtypes of von Willebrand's disease.9 Of particular interest to the present study is the fact that "acute" cigarette smoking increases the thrombotic response at high arterial shear conditions10 and that platelet-collagen adhesion is enhanced in blood from patients with hyperlipoproteinemia IIa and IIb under similar blood flow conditions.11
| Methods |
|---|
|
|
|---|
Nonsmoking Control Subjects
Seven healthy nonsmokers were recruited.
Atherosclerotic Patients
Six patients with angiographically documented severe peripheral
atherosclerotic arterial disease referred to the vascular surgery unit
of Ullevaal University Hospital were entered into the study. All
suffered from severe intermittent claudication, with pain at rest or
walking a distance less than 50 m. Two of the patients had a previous
history of myocardial infarction. The patients claimed not to have
smoked during the previous 2 years, and they were not suffering from
diabetes mellitus or other chronic diseases.
Two of the patients were taking pentoxifylline up to 24 hours before the perfusion experiment. The elimination half-life of pentoxifylline given as a conventional sustained-release tablet formulation is 3.4 hours.12 Since there were no differences between these two patients and the rest of the group, their data were retained in the analysis.
Cigarette Smokers
Seven healthy cigarette smokers were recruited. They were all
habitual smokers, smoking at least 10 cigarettes a day for more than 5
years.
Abstaining smokers. Abstaining smokers were willing to abstain from cigarette smoking during a 10-hour period before the blood donations.
Acute smoking. In a separate set of experiments, the same habitual cigarette smokers smoked one cigarette within 5 minutes before blood donations for perfusion experiments at a wall shear rate of 2600 s-1.
The acute effects of cigarette smoking in the ex vivo thrombosis model were recently reported in detail.10 From these studies it appears that smoking increases the thrombotic response only at 2600 s-1, and therefore we considered it unnecessary to repeat the studies on acute effects at 650 s-1.
Blood Samples
After venipuncture with a No. 19 Butterfly Infusion Set (Abbott
Laboratories), the first 5 mL of blood was collected into EDTA for
determination of platelet count and hematocrit (Auto Counter AC 920,
Swelab Instruments). The following 2.9 mL of blood was collected into
two Eppendorf tubes, one prefilled with 0.15 mL of 129 mmol/L sodium
citrate for determination of plasma fibrinogen and serum thiocyanate.
Plasma Fibrinogen and Serum Thiocyanate
Plasma fibrinogen levels were quantified in citrated plasma
according to Clauss.13 Clotting time was recorded with a
coagulometer KC10A (Amelung GmbH), and a standard curve was prepared
with human fibrinogen (Baxter Dade AG).
Thiocyanate was measured spectrophotometrically directly in serum as described by Degiampietro and Peheim,14 the method being adapted to a Cobas-Bio centrifugal analyzer (HoffmannLa Roche Ltd).
Ex Vivo Perfusion Experiments
Ex vivo perfusion experiments15 were performed at
37°C with collagen-coated coverslips positioned in parallel-plate
perfusion chambers.6 16 Purification and fibrillar
formation of collagen type III were previously reported in
detail.17 18 19 The fibrillar collagen suspension was
spray-coated19 onto washed Thermanox plastic coverslips
(Miles Laboratories) to a final density of approximately 20
µg/cm2. A density of 10 µg/cm2 gives a
maximal thrombogenic stimulus.20
After venipuncture and collection of blood samples, the next 50 mL of nonanticoagulated blood was drawn directly over the collagen surface by an occlusive roller pump (Gilson model M312) at a constant flow rate of 10 mL/min. The pump was placed distal to the perfusion chamber. Wall shear rates characteristic of healthy medium-sized (650 s-1) and moderately stenosed arteries (2600 s-1) were maintained at the collagen surface for 5 minutes. The different cross-sectional dimensions of the rectangular blood flow channel and the blood flow rate determine the wall shear rate.
Postperfusion, fixation, and epoxy resin embedding procedures were previously reported in detail.6 10 19 20
Morphometry
Platelet-collagen adherence, fibrin deposition, and thrombus
volume on the collagen surface were quantified by light
microscopy.21 Evaluations were performed on semithin
sections (1 µm) prepared perpendicular to the direction of the blood
flow 1 mm downstream from the upstream edge of the
coverslip.22 The sections were stained with basic fuchsin
and toluidine blue.21
Standard morphometry was used to assess the percentage of the surface covered with platelets (percent platelet adhesion) and with fibrin (percent fibrin deposition).21 The evaluations were performed with a Zeiss Standard 25 light microscope at x1000 magnification.
Thrombus area (micrometers squared per micrometers of sectional length) was assessed by computer-assisted morphometry (Kontron Vidas image-analysis unit, Zeiss). Thrombus volume (micrometers cubed per micrometers squared) was derived from the sectional thrombus area as previously described.22 The evaluations were carried out at x500 or x2000 magnification, depending on thrombus size.
Fibrinopeptide A and ß-Thromboglobulin
Plasma levels of fibrinopeptide A (FPA) and ß-thromboglobulin
(ß-TG) were measured distal to the perfusion chamber.7
At 4 minutes of perfusion time, blood samples (2x0.9 mL) were
collected immediately distal to the chamber, as previously described in
detail.23 The samples were collected successively during
15 seconds into syringes prefilled with 0.1 mL of 1000 IU heparin plus
1000 kallikrein inhibiting units Trasylol per milliliter of saline for
FPA and an anticoagulant mixture according to Ludlam and
Cash24 for ß-TG. The samples were immediately chilled on
ice. Further processing was done according to the manufacturers of the
respective kits (FPA from IMCO and ß-TG from Amersham).
Statistical Analysis
The significance of differences between groups was calculated
with the Mann-Whitney U test to avoid any assumptions about
the distribution of the material. Values of P<.05 were
considered significant.
| Results |
|---|
|
|
|---|
|
Plasma Fibrinogen and Serum Thiocyanate Levels
A higher plasma fibrinogen level was observed in the
atherosclerotic patients relative to the plasma levels of nonsmokers
(P<.005) and habitual smokers (P<.05) (Table 1
).
Serum thiocyanate levels were less than 70 µmol/L in all nonsmokers
and atherosclerotic patients, indicating that the information about
their smoking habits was correct. The mean serum thiocyanate level of
the habitual smokers exceeded 70 µmol/L and was significantly higher
than the serum levels in nonsmokers (P<.05) and
atherosclerotic patients (P<.005) (Table 1
).
Platelet-Collagen Adhesion
Abnormalities of platelet-collagen adhesion were not observed in
any of the groups at the two shear conditions (Tables 2
and 3
).
|
|
Thrombus Volume
The average thrombus volume at the wall shear rate of 650
s-1 was slightly lower in blood from the atherosclerotic
patients although not significantly different from the volumes observed
in blood from nonsmoking control subjects and habitual smokers (Table 2
).
The thrombus volume at 2600 s-1 was nearly twofold
increased in blood from cigarette smokers immediately after smoking one
cigarette, being significantly different from both atherosclerotic
patients (P<.01) and habitual smokers after 10 hours of
smoking abstinence (abstaining smokers) (P<.05) (Table 3
).
However, no significant differences were found between nonsmokers,
atherosclerotic patients, and abstaining smokers. Thus, the thrombus
volume in blood from habitual smokers was temporarily increased after
the smoking of a cigarette.
ß-TG Plasma Levels
The median ß-TG plasma levels were not different between the
various groups at 650 s-1 (Table 4
). In
contrast, at 2600 s-1 a significant difference in the
median ß-TG plasma levels (P<.05) was observed between
nonsmokers and abstaining smokers (Table 5
). However,
the increased thrombus formation immediately after cigarette smoking
was not reflected in an increased platelet release of ß-TG.
|
|
Fibrin Deposition on Collagen and FPA Plasma Levels
The surface coverage with fibrin was less than 5% at each wall
shear rate in blood from all groups (Tables 2
and 3
).
The median FPA plasma levels did not vary between the different groups
at 650 s-1 (Table 4
). However, a significant difference
(P<.05) in median FPA plasma levels was observed between
nonsmokers and atherosclerotic patients at 2600 s-1 (Table 5
).
| Discussion |
|---|
|
|
|---|
Thrombus formation in blood from habitual cigarette smokers was not enhanced after 10 hours of smoking abstinence. However, the smoking of a cigarette increased thrombus volume twofold at the highest arterial shear condition (2600 s-1). Thus, the thrombotic response was temporarily and reversibly upregulated by "acute" cigarette smoking. Previous findings have shown that this increased thrombus formation is due to enhanced platelet reactivity mediated through thromboxane A2, since aspirin reduces the thrombotic response to the level observed in healthy nonsmoking individuals.10
Evidence for changed platelet reactivity in patients with severe peripheral atherosclerosis was not found, since both platelet-collagen adhesion and thrombus volume were not different from the levels observed in nonsmoking control subjects. Also, the postchamber ß-TG plasma levels indicated a normal platelet reactivity at both shear rates. To eliminate the possible confounding effects of smoking, all the atherosclerotic patients participating in this study were currently nonsmokers. However, it should be emphasized that cigarette smoking is considered to be one of the major risk factors for developing intermittent claudication.27
Several prospective epidemiological studies have demonstrated a positive statistical correlation of plasma fibrinogen concentration with subsequent cardiovascular events after adjusting for other known risk factors.28 29 In our study the atherosclerotic patients had an elevated plasma fibrinogen level. At both shear rates, FPA generation after 4 minutes of perfusion was higher in the atherosclerotic patients, reaching significance versus nonsmokers at 2600 s-1. However, there was no individual correlation between the plasma fibrinogen level and platelet thrombus formation or the low fibrin deposition on the collagen surface.
Platelet aggregation is in general the precipitating event in acute arterial thrombosis. An increased risk for thrombosis in nonsmoking atherosclerotic patients apparently cannot be explained by an altered platelet function. However, persistent alterations in the endothelial lining of the vessels with defective defense mechanisms and/or disturbed blood flow patterns introduced by stenotic lesions may promote thrombogenesis.26 Atherosclerotic patients in general are prone to experience plaque ruptures,30 which may result in exposure of thrombogenic components such as tissue factor and collagen to the bloodstream.
The present results show that arterial ex vivo thrombus formation in blood from cigarette smokers is reversibly upregulated immediately after smoking and that the platelet thrombus formation is within the "normal" range after 10 hours of smoking abstinence. Patients with severe peripheral atherosclerotic disease who do not smoke show a collagen-induced platelet thrombus formation at arterial blood flow conditions with no signs of platelet hyporeactivity or hyperreactivity.
| Acknowledgments |
|---|
Received July 18, 1994; accepted October 31, 1994.
| References |
|---|
|
|
|---|
2. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500. [Medline] [Order article via Infotrieve]
3. Bithell TC. Thrombosis and antithrombotic therapy. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's Clinical Hematology. 9th ed. Philadelphia, Pa: Lea & Febiger; 1993:1515-1551.
4.
Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical
evidence of a chronic abnormality in platelet and vascular function in
healthy individuals who smoke cigarettes. Circulation. 1987;76:6-14.
5. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989. [Abstract]
6.
Sakariassen KS, Joss R, Muggli R, Kuhn H, Tschopp T, Sage H,
Baumgartner HR. Collagen type III induced ex vivo thrombogenesis in
humans: role of platelets and leukocytes in deposition of fibrin.
Arteriosclerosis. 1990;10:276-284.
7. Sakariassen KS, Roald HE, Salatti JA. Ex vivo models for studying thrombosis: special emphasis on shear rate dependent blood-collagen interactions. In: Hwang NHC, Turitto VT, Yen MRT, eds. Advances in Cardiovascular Engineering. New York, NY: Plenum Publishing Corp; 1992:151-174.
8.
Roux SP, Sakariassen KS, Turitto VT, Baumgartner HR. Effect
of aspirin and epinephrine on experimentally induced thrombogenesis in
dogs: a parallelism between in vivo and ex vivo thrombosis models.
Arterioscler Thromb. 1991;11:1182-1191.
9.
Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR,
Meyer D. Shear rate-dependent impairment of thrombus growth on collagen
in nonanticoagulated blood from patients with von Willebrand
disease and hemophilia A. Blood. 1992;80:988-994.
10.
Roald HE, Ørvim U, Bakken IJ, Barstad RM, Kierulf P,
Sakariassen KS. Modulation of thrombotic responses in moderately
stenosed arteries by cigarette smoking and aspirin ingestion.
Arterioscler Thromb. 1994;14:617-621.
11.
Cadroy Y, Lemozy S, Diquélou A, Ferriéres J,
Douste-Blazy P, Boneu B, Sakariassen KS. Human type II
hyperlipoproteinemia enhances platelet-collagen adhesion in flowing
nonanticoagulated blood. Arterioscler Thromb. 1993;13:1650-1653.
12. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97. [Medline] [Order article via Infotrieve]
13. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246. [Medline] [Order article via Infotrieve]
14. Degiampietro P, Peheim E. Determination of thiocyanate in plasma and saliva without deproteinisation and its validation as a smoking parameter. J Clin Chem Clin Biochem. 1987;25:711-717. [Medline] [Order article via Infotrieve]
15. Baumgartner HR. Effects of anticoagulation on the interaction of human platelets with subendothelium in flowing blood. Schweiz Med Wochenschr. 1976;106:1367-1368. [Medline] [Order article via Infotrieve]
16. Sakariassen KS, Aarts PAMM, deGroot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med. 1983;102:522-535. [Medline] [Order article via Infotrieve]
17. Miller EF, Rhodes RK. Preparation and characterization of the different types of collagen. Methods Enzymol. 1982;82:33-64.
18. Bruns RR, Gross J. High resolution analysis of the modified quarter-stagger model of the collagen fibril. Biopolymers. 1977;13:931-941.
19. Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol. 1989;169:37-70. [Medline] [Order article via Infotrieve]
20. Sakariassen KS, Weiss HJ, Baumgartner HR. Upstream thrombus growth impairs downstream thrombogenesis in nonanticoagulated blood: effect of procoagulant artery subendothelium and non-procoagulant collagen. Thromb Haemost. 1991;65:596-600. [Medline] [Order article via Infotrieve]
21. Baumgartner HR, Muggli R. Adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: Gordon JL, ed. Platelets in Biology and Pathology. Amsterdam, the Netherlands: Elsevier, North-Holland; 1976:23-60.
22. Sakariassen KS, Kuhn H, Muggli R, Baumgartner HR. Growth and stability of thrombi in flowing citrated blood: assessment of platelet surface interactions with computer-assisted morphometry. Thromb Haemost. 1988;60:390-398.
23. Roald HE, Barstad RM, Engen A, Kierulf P, Skjørten F, Sakariassen KS. HN-11500: a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost. 1994;71:103-109. [Medline] [Order article via Infotrieve]
24. Ludlam CA, Cash JI. Studies on the liberation of ß-thromboglobulin from human platelets in vitro. Br J Haematol. 1976;33:239-247. [Medline] [Order article via Infotrieve]
25.
Kinlough-Rathbone RL, Packham MA, Mustard JF. Vessel injury,
platelet adherence, and platelet survival. Arteriosclerosis. 1983;3:529-546.
26. Sakariassen KS, Barstad RM. Mechanisms of thromboembolism at arterial plaques. Blood Coagul Fibrinolysis. 1993;4:615-625.[Medline] [Order article via Infotrieve]
27. Kannel WB, Shurtleff D. The Framingham study: cigarettes and the development of intermittent claudication. Geriatrics. 1973;28:61-68. [Medline] [Order article via Infotrieve]
28. Hultin MB. Fibrinogen and factor VII as risk factors in vascular disease. In: Coller BS, ed. Progress in Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders; 1991;10:215-241.
29.
Johansson J, Egberg N, Johnsson H, Carlson LA. Serum
lipoproteins and hemostatic function in intermittent claudication.
Arterioscler Thromb. 1993;13:1441-1448.
30.
Falk E. Plaque rupture with severe pre-existing stenosis
precipitating coronary thrombosis: characteristics of coronary
atherosclerotic plaques underlying fatal occlusive thrombi. Br
Heart J. 1983;50:127-134.
This article has been cited by other articles:
![]() |
M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Hagberg, H. E. Roald, and T. Lyberg Platelet Activation in Flowing Blood Passing Growing Arterial Thrombi Arterioscler Thromb Vasc Biol, July 1, 1997; 17(7): 1331 - 1336. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |